SavedAdd your journal

Journals / Haydarpaşa Numune Medical Journal / 2020 / Cilt: 60 - Sayı: 4

Fetomaternal Effects of TSH Values in the Initial Stage of Pregnancy

Ali Doğukan ANĞIN
İsmet GÜN
Yasemin SEVİNÇ
Onder SAKİN
Muzaffer Seyhan ÇIKMAN
Serem URUŞ
Pages
317–321
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Discussion and Conclusion: In cases of subclinical hypothyroidism during pregnancy, refraining from medication does not cause PPO.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: To examine the fetomaternal effects of TSH values considered to be high (≥2.5 and 0.3 and <4 μIU/mL in the first trimester of their pregnancy who were followed up in our clinic until giving birth were included to the study.
📊
Key Findings & Data:The 518 patients meeting the criteria were divided into 2 groups according to their initial TSH values; Group 1 consisted of patients with TSH <2.5 μIU/mL (n=410), and Group 2 of patients with TSH ≥2.5 and <4 μIU/mL (n=108).
💡
Conclusion & Impact:Discussion and Conclusion: In cases of subclinical hypothyroidism during pregnancy, refraining from medication does not cause PPO.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Introduction: To examine the fetomaternal effects of TSH values considered to be high (≥2.5 and 0.3 and <4 μIU/mL in the first trimester of their pregnancy who were followed up in our clinic until giving birth were included to the study. Patient files were reviewed retrospectively. The 518 patients meeting the criteria were divided into 2 groups according to their initial TSH values; Group 1 consisted of patients with TSH <2.5 μIU/mL (n=410), and Group 2 of patients with TSH ≥2.5 and <4 μIU/mL (n=108). Demographic char- acteristics and poor pregnancy outcomes (PPO) of the patients were compared. Results: Comparing the demographic characteristics of the two groups formed according to the patients’ TSH values at the onset of their pregnancy, no statistically significant differences were found (p<0.05). When the two groups were compared in terms of poor pregnancy outcomes (PPO), no statistically significant difference was found either (p=.852; OR: 1.067; CI: 0.541-2.102). Discussion and Conclusion: In cases of subclinical hypothyroidism during pregnancy, refraining from medication does not cause PPO.

🔖

Cite This Article

ANĞIN, A. D., GÜN, İ., SEVİNÇ, Y., SAKİN, O., ÇIKMAN, M. S., URUŞ, S. (2020). Fetomaternal Effects of TSH Values in the Initial Stage of Pregnancy. Haydarpaşa Numune Medical Journal, Cilt: 60 - Sayı: 4, 317–321. https://ajindex.com/articles/165921

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Koyuncu K, Turgay B, Söylemez F. Iodine deficiency in preg- nant women at first trimester in Ankara. J Turk Ger Gynecol Assoc 2019;20:37–40
  2. Stagnaro-Green A, Sullivan S, Pearce EN. Iodine supplementa- tion during pregnancy and lactation. JAMA 2012;308:2463–4. 3. http://temd.org.tr/admin/uploads/tbl_kilavuz/ 20180518105146-2018-05-18tbl_kilavuz105136.pdf (erişim 07.11.2018) 4. Šálek T, Dhaifalah I, Langova D, Havalová J. Maternal thy- roid-stimulating hormone reference ranges for first trimester screening from 11 to 14 weeks of gestation. J Clin Lab Anal 2018;32:e22405
  3. Krassas GE, Poppe K, Glinoer D. Thyroid function and human reproductive health. Endocr Rev 2010;31:702–55
  4. Thung SF, Funai EF, Grobman WA. The cost-effectiveness of universal screening in pregnancy for subclinical hypothy- roidism. Am J Obstet Gynecol 2009;200:267.e1–7
  5. Springer D, Jiskra J, Limanova Z, Zima T, Potlukova E. Thyroid in pregnancy: From physiology to screening. Crit Rev Clin Lab Sci 2017;54:102–16
  6. Männistö T, Surcel HM, Ruokonen A, Vääräsmäki M, Pouta A, Bloigu A, et al. Early pregnancy reference intervals of thyroid hormone concentrations in a thyroid antibody-negative preg- nant population. Thyroid 2011;21:291–8
  7. Casey BM. The debate on thyroid screening during pregnancy continues. Obstet Gynecol. 2014 Jul;124(1):8–9
  8. Vila L, Velasco I, González S, Morales F, Sánchez E, Torrejón S, et al. Controversies in endocrinology: On the need for univer- sal thyroid screening in pregnant women. Eur J Endocrinol 2013;170:R17–30
  9. Haddow JE, McClain MR, Lambert-Messerlian G, Palomaki GE,Canick JA, Cleary-Goldman J, et al; First and Second Trimester Evaluation of Risk for Fetal Aneuploidy Research Consortium. Variability in thyroid-stimulating hormone suppression by human chorionic [corrected] gonadotropin during early preg- nancy. J Clin Endocrinol Metab 2008;93:3341–7
  10. Negro R, Stagnaro-Green A. Clinical aspects of hyperthy- roidism, hypothyroidism, and thyroid screening in pregnancy. Endocr Pract 2014;20:597–607
  11. De Groot L, Abalovich M, Alexander EK, Amino N, Barbour L, Cobin RH, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012;97:2543–65
  12. Martínez M, Soldevila B, Lucas A, Velasco I, Vila L, Puig- Domingo M. Hypothyroidism during pregnancy and its as- sociation to perinatal and obstetric morbidity: a review. En- docrinol Diabetes Nutr 2018;65